Dr. Jennifer Litton is a board-certified medical oncologist and professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, TX, where she is vice president of clinical research. She also is a member of the Breast Immuno-Oncology Task Force of the National Cancer Institute.

Dr. Litton joins us for this episode to talk about the side effects that may be caused by the two immunotherapy medicines approved for breast cancer: Keytruda (chemical name: pembrolizumab) and Tecentriq (chemical name: atezolizumab).

Listen to the podcast to hear Dr. Litton explain: